This map shows the geographic impact of M Weil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Weil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Weil more than expected).
This network shows the impact of papers produced by M Weil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Weil. The network helps show where M Weil may publish in the future.
Co-authorship network of co-authors of M Weil
This figure shows the co-authorship network connecting the top 25 collaborators of M Weil.
A scholar is included among the top collaborators of M Weil based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with M Weil. M Weil is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Khayat, D., M Weil, C. Soubrane, & C Jacquillat. (1988). [LAK cells and immunotherapy of cancer].. PubMed. 75(1). 3–7.2 indexed citations
11.
Khayat, D., François Lokiec, Jean-Pierre Bizzari, et al.. (1987). Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.. PubMed. 47(24 Pt 1). 6782–5.47 indexed citations
Brasnu, Daniel, et al.. (1986). Short-term results of the combination of cis-platinum, 5-fluorouracil and bleomycin in advanced upper aerodigestive tract cancers.. PubMed. 12(1-3). 211–7.
14.
Boiron, M, C Jacquillat, Marion Marty, M Weil, & Christian Gisselbrecht. (1981). Anthracyclines in the treatment of acute nonlymphocytic leukemias.. PubMed. 65 Suppl 4. 73–6.5 indexed citations
15.
Auclerc, G, et al.. (1981). [Hodgkin's disease: characteristics and prognosis of forms with initial bone marrow involvement (author's transl)].. PubMed. 10(2). 95–100.4 indexed citations
16.
Jacquillat, C, et al.. (1976). [Prognostic factors in chronic myeloid leukemia. Apropos of 798 cases].. PubMed. 126(6-7). 515–20.1 indexed citations
17.
Jacquillat, C, et al.. (1975). [New data about oligoblastic leukemias. Apropos of an analysis of 120 cases].. PubMed. 4(13). 947–52.3 indexed citations
18.
Weil, M, et al.. (1967). [A new antibiotic with antineoplastic activity: rubidomycin (13.057 R.P.)].. PubMed. 17(8). 955–9.2 indexed citations
19.
Tanzer, J, M Boiron, C Jacquillat, et al.. (1967). [Effects of rubidomycin in chronic myeloid leukemia].. PubMed. 15(19). 943–4.1 indexed citations
20.
Tanzer, J, C Jacquillat, M Weil, et al.. (1966). [Effects of hydroxyurea in chronic myeloid leukemia. Preliminary study].. PubMed. 74(56). 2929–30.4 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.